Navigation Links
Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
Date:12/10/2007

ng both complete remissions and the fact that the drug has been very well-tolerated."

CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown in preclinical studies to represent a synergistic ratio for use in combination chemotherapy. CPX-351 represents a new approach to developing drug combinations in which drug ratios are pre-selected based on synergistic anti-tumor activity observed preclinically and where the ratios are maintained in patients through Celator's proprietary CombiPlex(TM) technology platform.

"According to the study results, CPX-351 maintained the synergistic ratio of cytarabine and daunorubicin in patients. In addition, evidence of clinical benefit seen in this Phase I study is very encouraging and provides substantial additional support to continue to advance CPX-351 in clinical development," said Andrew Janoff, Ph.D., CEO of Celator.

About Celator

Celator Pharmaceuticals, Inc. is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in a Phase II trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase I trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX-571, now positioned to advance to Phase I trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Amerivet Solutions, LLC ( AMERIVET ), ... government from Federal to Municipal, is pleased to ... include complex metal design and fabrication manufacturing. "We ... aluminum parts for the Defense Logistics Agency (DLA) ... service government contracts," states Richard Bergen , ...
(Date:6/19/2013)... 2013 DST Health Solutions, LLC (DSTHS), a ... plans, integrated delivery systems, and health care providers, has ... Service (MDMS) has jumped significantly. A ... pricing of medical prescription drug claims, MDMS ... medical drug claims processes. As specialty drug demand grows ...
(Date:6/19/2013)... 19, 2013 /PRNewswire-iReach/ -- Today leading web researchers Change ... ranking Pharmaceutical web sites for usability, engagement, and conversion. ... Cloud platform, which compares how people experience sites with ... The top three performers are easier to ... The bottom performers have usability problems, lack aspects of ...
Breaking Medicine Technology:Amerivet Solutions Expands to Manufacture Complex Metal Designs 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2
... Cellular Dynamics International, Inc. (CDI) today announced ... will distribute CDI,s iCell® Cardiomyocytes , the first commercially ... Japan. This distribution agreement brings the vision ... Thomson and Dr. Shinya Yamanaka , a step ...
... StreamVenue Healthcare has partnered its "plug and play" ... Medicine to teach, and to better manage post-surgical patient ... surgeons and physical therapists to view cases and discuss ... cohesive communication and creates a live classroom for teaching ...
Cached Medicine Technology:iPS Academia Japan, Inc. to Distribute Cellular Dynamics' iCell® Products in Japan 2iPS Academia Japan, Inc. to Distribute Cellular Dynamics' iCell® Products in Japan 3StreamVenue Healthcare Connects Endoscopy Technology With Athletic Trainers 2
(Date:6/19/2013)... Bellingham, Washington (PRWEB) June 19, 2013 ... before physicians deem it medically necessary, according to ... Maternal and Child Health Journal. The results of ... advocating for more than a decade – that ... care, and maintaining a healthy body weight. Fairhaven ...
(Date:6/19/2013)... Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig,s ... be classified into four distinct stages, report pathologists with ... Pennsylvania in the Annals of Neurology . This ... shows, for the first time, how the fatal degenerative ... central nervous system to other regions of brain and ...
(Date:6/19/2013)... Amsterdam, June 19, 2013 Elsevier, a world-leading ... and services, announced today the publication of the ... diagnosis and management of osteoporosis in postmenopausal women ... . , Published in 2009 in Maturitas ... and this update is timely with an additional ...
(Date:6/19/2013)... The former internist for the St. Louis Rams ... as director of prevention and wellness at St. Luke’s ... encounter with a metabolic syndrome diagnosis and a happenstance ... that he credits with sparking the paradigm-shift that has ... , “The average medical student gets 30 minutes of ...
(Date:6/19/2013)... 19, 2013 Recently, SoCal CEO Magazine ... held their third in a series of six workshops where ... Respect and helped place the mosaic tiles in their permanent location ... parents, Cathy and Greg Maxwell. , This mural project began ... that took root over three years ago with the goal ...
Breaking Medicine News(10 mins):Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2
... An Annualized Yield Of 9.5%, LARGO, Fla., Feb. ... (TSX Venture Exchange: UVI) Board of Directors,today declared its ... payable February 28, 2008 to stockholders of record at ... are pleased to continue the quarterly dividend policy which ...
... start in two years, California researcher says , , FRIDAY, Feb. ... stopped the progress of the disease in 90 percent of ... vaccine turned the cancer into a chronic, manageable disease," said ... the Feb. 1 issue of Cancer Research . , ...
... The globally active precious,metal and technology group Heraeus ... Interventional Business of Synovis Life,Technologies, Inc., based in ... 31, 2008. With this acquisition, the Heraeus Medical,Components ... facilities in the,U.S., Germany, Switzerland and Puerto Rico., ...
... Feb. 1 Lifespring Health,sponsors the Kaiser Permanente San ... important charity event benefiting the Hemophilia Foundation of,Northern California, ... Family House., Set to take place on Feb. ... mile course is ranked as one of the most ...
... Brian Piwek to Assist in Generating New Retail ... Skinvisible, Inc. (OTC,Bulletin Board: SKVI) ( http://www.skinvisible.com ), ... of patented dermatology,products with their proprietary polymer delivery ... been selected as a new member of,the Company,s ...
... In healthy people, both sleepiness and vigilance show a ... When core body temperature is high during the daytime, ... Conversely, when core body temperature is low at ... optimal sleep. Among those suffering from narcolepsy, however, ...
Cached Medicine News:Health News:Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share 2Health News:Experimental Vaccine Halts Prostate Cancer in Mice 2Health News:Experimental Vaccine Halts Prostate Cancer in Mice 3Health News:Heraeus Strengthens Medical Components Business 2Health News:Skinvisible Appoints New Board Member 2Health News:Skinvisible Appoints New Board Member 3Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 3
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... HEp-2 cell line that has been genetically ... autoantibodies, without affecting the other ANA patterns ... worldwide on the HEp-2000 ANA substrate, which ... used in place of standard HEp-2 cells ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
Medicine Products: